Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01314352 · ClinicalTrials.gov registry record · Phase 1
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
A Phase 1 study of Fed, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01314352: Completed Phase 1 study of Fed, sponsored by Dr. Reddy's Laboratories Limited.
NCT01314352 is a Phase 1 study of Fed that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01314352, a Phase 1 study of Fed, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex® 5 mg tablet in healthy subjects under fed conditions.
Conditions Studied
Interventions
- DRUG Desloratadine
Study Locations (1)
Florida
- SFBC, Ft. Myers, Inc., - Fort Myers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2005-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
What the finished NCT01314352 record still lists
NCT01314352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Fed appearing as the primary indexed condition, and to 1 intervention - of which Desloratadine is the first listed.
NCT01314352 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01314352 about?
NCT01314352 is a clinical study titled "Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions". The purpose of this study is to compare the rate and extent of absorption of Dr. Reddy's Desloratadine 5 mg tablet to that of Clarinex® 5 mg tablet in healthy subjects under fed conditions.
What is the current status of trial NCT01314352?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2005-12. Estimated completion is 2006-03.
What conditions does trial NCT01314352 study?
This clinical trial studies the following conditions: Fed.
What interventions are being tested in trial NCT01314352?
The interventions under investigation include: Desloratadine (DRUG).
Who is sponsoring clinical trial NCT01314352?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01314352 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01314352's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia